Clinical trials: Leishmaniasis
Cutaneous Leishmaniasis
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
This study is to determine the effectiveness and safety of WR 279,396, a topical cream for the treatment of cutaneous leishmaniasis.
- Trial name
- NCT00703924
- Testing
- WR 279,396
- Where
- 2 sites in France, Tunisia
- Volunteers
- 92 people
- Sponsor
- U.S. Army Medical Research and Development Command
Post-kala-azar Dermal Leishmaniasis
A Study to Assess Safety and Efficacy of a Leishmania Vaccine to Prevent Post Kala Azar Dermal Leishmaniasis (PKDL)
The actual format of the anticipated LEISH3 trial is under review.
- Trial name
- LEISH3 (NCT04107961)
- Testing
- Vaccine
- Sponsor
- University of York
Visceral Leishmaniasis
A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh
Kala azar (KA) or visceral leishmaniasis (VL) is endemic in several districts of Bangladesh with the highest incidence in Mymensingh, Pabna and Tangail districts.
- Trial name
- NCT01240473
- Testing
- Randomized trial for treatment of kala azar in Bangladesh
- Where
- Bangladesh
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Visceral Leishmaniasis
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
The overall objective of this trial is to identify a safe and effective combination, (coadministration) short course treatment for the treatment of visceral leishmaniasis which could be easily deployed in a control programme and…
- Trial name
- NCT00696969
- Testing
- Amphotericin B Deoxycholate, Ambisome + Miltefosine, Ambisome and Paromomycin
- Where
- 2 sites in India
- Volunteers
- 634 people
- Sponsor
- Drugs for Neglected Diseases
Leishmaniasis, Cutaneous, Insect Bites
A Clinical Study to Develop an Uninfected Sand Fly Biting Protocol
The disease leishmaniasis mainly occurs in hot and tropical countries, affects millions of people and causes around 20,000 deaths across the world every year.
- Trial name
- FLYBITE (NCT03999970)
- Testing
- Sand fly bite
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of York
Skin and Connective Tissue Diseases, Neglected Tropical Diseases
Early Detection and AI-Based Management of Skin-Related Neglected Tropical Diseases in Sub-Saharan Africa by Frontline Health Workers
Skin-related Neglected Tropical Diseases (Skin NTDs) affect about 1.8 billion people worldwide, particularly in poor and rural communities where healthcare access is limited.
- Conditions
- Skin and Connective Tissue Diseases, Neglected Tropical Diseases, Leprosy, Buruli Ulcer
- Trial name
- SkincAIr (NCT07506967)
- Testing
- A mobile app with AI functionality for diagnosing skin-related NTDs
- Where
- 5 sites in Democratic Republic of the Congo, Ethiopia and 3 more
- Volunteers
- 2,420 people
- Sponsor
- Kenya Medical Research Institute
Cutaneous Leishmaniases
Complex Cutaneous Leishmaniasis Healing Study in Algeria
This study evaluates the effect of clean wound management and dressing on complex zoonotic cutaneous leishmaniasis caused by L. major in the MENA region (Algeria). The patients will participate in the wound dressing themselves.
- Trial name
- LeiClean (NCT03292835)
- Testing
- LeiProtect®
- Where
- Germany
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- K. W. Stahl
Leishmaniasis
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers
The purpose of this study is to determine the safety, tolerability, and immunogenicity in healthy adult subjects of an investigational vaccine being developed for the prophylaxis of visceral leishmaniasis.
- Trial name
- NCT01484548
- Testing
- LEISH-F3 + GLA-SE, LEISH-F3 alone
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Visceral Leishmaniasis, Kala Azar
Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar
A cluster-randomized vector control trial in Bihar, India, and neighboring Nepal, will test the efficacy of long-lasting impregnated bednets (LLINs, Permanets) for reducing visceral leishmaniasis incidence.
- Trial name
- KALANET (NCT00318721)
- Testing
- Long Lasting Impregnated Nets (LLIN)
- Where
- 2 sites in India, Nepal
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- London School of Hygiene and Tropical Medicine
Cutaneous Leishmaniasis
Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India
Infections caused by the protozoan parasite Leishmania include cutaneous (CL), mucosal (ML) and visceral leishmaniasis (VL). Over 12 million people currently suffer from leishmaniasis, and approximately 2 million new cases occur…
- Trial name
- NCT01661296
- Testing
- RFH therapy, Sodium stibogluconate
- Where
- India
- Volunteers
- 100 people
- Sponsor
- Sarder Patel Medical College
Visceral Leishmaniasis
An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis
It is a randomized, double-blind, multi-center, two-arm study intended to assess the safety and efficacy of three different doses/dose regimens of paromomycin administered intramuscularly as follows: 11 mg/kg/day for 14 days and…
- Trial name
- NCT00629031
- Testing
- Paromomycin
- Where
- India
- Volunteers
- 329 people
- Sponsor
- Banaras Hindu University
Leishmaniasis, Cutaneous Leishmaniases
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
The disease leishmaniasis mainly occurs in hot and tropical countries, affects millions of people and causes around 20,000 deaths across the world every year.
- Conditions
- Leishmaniasis, Cutaneous Leishmaniases, Insect Bites
- Trial name
- LEISHChallenge (NCT04512742)
- Testing
- biting by Phlebotomus duboscqi infected with Leishmania major
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of York
Cutaneous Leishmaniasis
Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
Cutaneous leishmaniasis is endemic in the New World from approximately the US-Mexican border through Central America and the Northern part of South America down to the level of Rio de Janeiro.
- Trial name
- NCT01380314
- Testing
- Miltefosine + Imiquimod
- Where
- Bolivia
- Volunteers
- 60 people
- Sponsor
- Foundation Fader
Visceral Leishmaniasis
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
The purpose of this trial is to evaluate the efficacy of single dose amphotericin B in the treatment of Visceral Leishmaniasis (VL) in India.
- Trial name
- NCT00628719
- Testing
- Liposomal Amphotericin B, amphotericin B deoxycholate
- Where
- India
- Volunteers
- 400 people
- Sponsor
- Banaras Hindu University
Leishmaniasis, Cutaneous
Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis
This study will evaluate the safety of the Leish-111f + MPL-SE vaccine in adult patients with cutaneous leishmaniasis.
- Trial name
- NCT00111553
- Testing
- Leish-111f + MPL-SE vaccine
- Where
- 2 sites in Brazil
- Volunteers
- 45 people
- Sponsor
- Access to Advanced Health Institute (AAHI)
Cutaneous Leishmaniasis
Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite
This study will evaluate the safety of the Leish-111f + MPL-SE vaccine in adult subjects with a previous exposure to the Leishmania parasite (but without current or past history of leishmaniasis).
- Trial name
- NCT00121849
- Testing
- Leish-111f + MPL-SE vaccine
- Where
- Colombia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Access to Advanced Health Institute (AAHI)
Cutaneous Leishmaniasis
Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨
The purpose of this trial is to determine the efficacy and safety of a combined therapy using thermotherapy (TT) (one session, 50 degrees Celsius for 30") + miltefosine at a standard dose of 2.5 mg/kg/day for 21 days for the…
- Trial name
- NCT02687971
- Testing
- Miltefosine
- Where
- 2 sites in Colombia, Peru
- Volunteers
- 130 people
- Sponsor
- Drugs for Neglected Diseases
Visceral Leishmaniasis
Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya
Visceral leishmaniasis (VL) is a fatal disease caused by Leishmania parasites and transmitted by female phlebotomine sandflies. The disease is a serious public health problem in eastern Africa; including Kenya where an estimated…
- Trial name
- rK28-AccDemo (NCT05386875)
- Testing
- rK28
- Where
- 4 sites in Kenya
- Volunteers
- 625 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Leishmaniasis, Cutaneous, Leishmaniasis, Mucocutaneous
Compassionate Use of Sodium Stibogluconate (Pentostam) for Cutaneous and Mucocutaneous New World Leishmaniasis
Patients with biopsy proven new world cutaneous or mucocutaneous leishmaniasis will be treated with sodium stibogluconate (Pentostam).
- Trial name
- NCT00508963
- Testing
- sodium stibogluconate (Pentostam)
- Where
- United States
- Sponsor
- University of California, San Francisco
Cutaneous Leishmaniasis
Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants
While vaccination against cutaneous leishmaniasis, a chronic ulcerating protozoan infection of the skin, has been possible for decades using live parasites, the production and storage of live cultures are difficult.
- Trial name
- NCT00001906
- Testing
- Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)